Zacks Research Has Positive Estimate for Maximus Q1 Earnings

Maximus, Inc. (NYSE:MMS) – Equities researchers at Zacks Research upped their Q1 2025 earnings per share estimates for Maximus in a report released on Wednesday, December 11th. Zacks Research analyst R. Department now forecasts that the health services provider will post earnings of $1.39 per share for the quarter, up from their previous estimate of $1.38. The consensus estimate for Maximus’ current full-year earnings is $5.89 per share. Zacks Research also issued estimates for Maximus’ Q2 2025 earnings at $1.44 EPS, Q3 2025 earnings at $1.50 EPS, Q4 2025 earnings at $1.52 EPS, FY2025 earnings at $5.84 EPS, Q2 2026 earnings at $1.19 EPS, Q3 2026 earnings at $1.45 EPS, Q4 2026 earnings at $1.23 EPS, FY2026 earnings at $5.05 EPS and FY2027 earnings at $5.29 EPS.

Separately, StockNews.com cut Maximus from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th.

Maximus Stock Down 1.2 %

MMS opened at $69.85 on Friday. The stock’s 50 day moving average price is $82.58 and its 200 day moving average price is $86.59. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.49 and a quick ratio of 1.49. The stock has a market cap of $4.21 billion, a P/E ratio of 13.97 and a beta of 0.73. Maximus has a 12 month low of $69.72 and a 12 month high of $93.97.

Maximus Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Saturday, November 30th. Stockholders of record on Friday, November 15th were issued a $0.30 dividend. This represents a $1.20 annualized dividend and a dividend yield of 1.72%. The ex-dividend date was Friday, November 15th. Maximus’s dividend payout ratio (DPR) is presently 24.00%.

Insider Activity at Maximus

In other Maximus news, insider Michelle F. Link sold 2,208 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $73.83, for a total value of $163,016.64. Following the completion of the sale, the insider now directly owns 6,567 shares of the company’s stock, valued at approximately $484,841.61. This represents a 25.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Raymond B. Ruddy acquired 3,490 shares of Maximus stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $71.46 per share, with a total value of $249,395.40. Following the completion of the purchase, the director now owns 112,520 shares in the company, valued at approximately $8,040,679.20. This represents a 3.20 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Maximus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Inspire Advisors LLC boosted its position in shares of Maximus by 1.4% in the second quarter. Inspire Advisors LLC now owns 8,768 shares of the health services provider’s stock worth $751,000 after buying an additional 121 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of Maximus by 4.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 3,179 shares of the health services provider’s stock valued at $272,000 after buying an additional 136 shares in the last quarter. Petrus Trust Company LTA raised its holdings in shares of Maximus by 2.7% during the 3rd quarter. Petrus Trust Company LTA now owns 7,084 shares of the health services provider’s stock valued at $660,000 after purchasing an additional 185 shares in the last quarter. WR Wealth Planners LLC raised its holdings in Maximus by 4.6% during the second quarter. WR Wealth Planners LLC now owns 4,525 shares of the health services provider’s stock valued at $388,000 after buying an additional 198 shares in the last quarter. Finally, Holocene Advisors LP boosted its stake in shares of Maximus by 6.5% during the 3rd quarter. Holocene Advisors LP now owns 3,927 shares of the health services provider’s stock worth $366,000 after acquiring an additional 239 shares in the last quarter. 97.21% of the stock is currently owned by hedge funds and other institutional investors.

Maximus Company Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.